STAA Earnings Date: Nov 4, 2026 (Estimated) — STAAR Surgical Company
NASDAQ · Healthcare · Medical Instruments & Supplies
Updated
When is STAA's next earnings date?
STAAR Surgical Company (STAA) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.05 on revenue of $78.7M.
How did STAA do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), STAAR Surgical Company posted EPS of $0.16 versus the $0.22 estimate, a miss of 15.8%. Revenue was $93.5M against a $90.6M estimate. The stock's 1-day post-earnings move was -0.3%.
How much does STAA stock move after earnings?
STAA beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.0% (up or down) in the day after earnings.
About STAAR Surgical Company
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | 0.22 | 0.16 | -15.79% | $93.5M | ❌ Miss | -0.31% | -2.95% | -10.82% |
| 2026-05-13 | Q1 2026 | 0.06 | 0.10 | +66.67% | $93.5M | ✅ Beat | +8.88% | +12.41% | -3.50% |
| 2026-03-03 | Q4 2025 | 0.11 | -0.13 | -218.18% | $57.8M | ❌ Miss | +1.59% | -8.93% | +2.17% |
| 2025-11-05 | Q3 2025 | 0.17 | 0.18 | +5.88% | $94.7M | ✅ Beat | +5.47% | +2.38% | +0.51% |
| 2025-08-06 | Q2 2025 | -0.60 | -0.34 | +43.33% | $44.3M | ✅ Beat | +0.19% | +4.87% | +3.87% |
| 2025-02-11 | Q4 2024 | 0.00 | -0.69 | -100.00% | $49.0M | ❌ Miss | -24.68% | -18.78% | -20.43% |
| 2024-08-07 | Q2 2024 | 0.24 | 0.15 | -37.50% | $99.0M | ❌ Miss | +11.03% | -3.44% | -14.39% |
| 2024-05-07 | Q1 2024 | 0.04 | -0.07 | -275.00% | $77.4M | ❌ Miss | -12.07% | -6.43% | -13.25% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q1 FY25 · $42.6M total
| Segment | Share | Revenue | YoY | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 |
|---|---|---|---|---|---|---|---|
| Implantable Collamer Lenses | 97.4% | $41.5M | -46.2% | $81.1M | $74.6M | $77.2M | $99.4M |
| Other Surgical Products | 2.6% | $1.1M | +432.2% | — | $1.8M | $205K | — |
By region
Q3 FY19 · $39.1M total
| Segment | Share | Revenue | YoY | Q1 FY18 | Q2 FY18 | Q3 FY18 | Q4 FY18 |
|---|---|---|---|---|---|---|---|
| CHINA | 47.0% | $18.4M | +37.5% | $7.9M | $14.0M | $13.3M | $10.8M |
| Other Countries | 34.2% | $13.3M | +7.5% | $10.1M | $13.2M | $12.4M | $7.7M |
| JAPAN | 18.8% | $7.3M | +22.3% | $5.1M | $6.7M | $6.0M | $5.4M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.